Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0782 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| MK0782 | DRUG | - |
Inclusion Criteria: * Healthy male or non pregnant female * 18 years of age or older (age at consent) * Able to abstain from alcohol, tobacco, spicy foods, limit coffee * Able to avoid strenuous activity * Able to read and fill out a study diary Exclusion Criteria: * You have participated in an i...
MK0782 is an investigational small molecule being studied for the treatment of stomach ulcer and duodenal ulcer. It is in Phase 2 clinical development. The drug is being evaluated for its effects on gastrointestinal erosions, particularly in combination with low-dose aspirin.
MK0782 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with stomach and duodenal ulcers.
MK0782 is currently in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind study. The drug is still investigational and has not been approved by regulatory authorities for any use.
MK0782 has one completed clinical trial registered under NCT00543868, titled "MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001)." This Phase 2 study enrolled 462 participants and evaluated the drug's effect on stomach and duodenal ulcers.
MK0782 is also known by its trial identifier 0782-001, which refers to the specific clinical study. No other alternative names for the drug itself have been disclosed. The drug is being studied under the code name MK0782 by its developer.